Accent Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.8K Buy
1,005
+257
+34% +$6.41K 0.01% 142
2026
Q2
$18.1K Buy
748
+180
+32% +$3.07K 0.01% 161
2026
Q1
$8.8K Buy
568
+188
+49% +$3.12K ﹤0.01% 212
2025
Q4
$7.21K Buy
380
+310
+443% +$4.45K ﹤0.01% 243
2025
Q3
$647 Sell
70
-180
-72% -$1.87K ﹤0.01% 371
2025
Q2
$2.85K Buy
+250
New +$2.7K ﹤0.01% 372

Other funds holding NRIX

Accent Capital Management's NRIX Position: Q3 2026 in Review

Accent Capital Management increased its Nurix Therapeutics (NRIX) stake by 34% in Q3 2026, buying an estimated $6.41K and bringing the position to 1,005 shares worth $23.8K. The position accounts for 0.01% of the portfolio, ranked #142.

Accent Capital Management first reported a position in NRIX in Q2 2025 and has held it in 6 quarters since. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Accent Capital Management held 1,005 shares of Nurix Therapeutics worth $23.8K as of Q3 2026.
  • Accent Capital Management bought 257 Nurix Therapeutics shares in Q3 2026, an estimated $6.41K.
  • Nurix Therapeutics made up 0.01% of Accent Capital Management's portfolio in Q3 2026, its #142 holding.
  • Accent Capital Management first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Accent Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.